Tracking the relevant researches of CADD drug development against COVID-19
Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. [DrugBank]
Serine/threonine-protein kinase B-raf (Humans); RAF proto-oncogene serine/threonine-protein kinase (Humans); Vascular endothelial growth factor receptor 3 (Humans); Vascular endothelial growth factor receptor 2 (Humans); Receptor-type tyrosine-protein kinase FLT3 (Humans); Platelet-derived growth factor receptor beta (Humans); Mast/stem cell growth factor receptor Kit (Humans); Fibroblast growth factor receptor 1 (Humans); Proto-oncogene tyrosine-protein kinase receptor Ret (Humans); Vascular endothelial growth factor receptor 1 (Humans) [DrugBank]
No large changes in QTc interval were observed. After one 28-day treatment cycle, the largest mean QTc interval change of 8.5 ms (upper bound of two-sided 90% confidence interval, 13.3 ms) was observed at 6 hours post-dose on day 1 of cycle 2. [DrugBank]
Tips: Click on the link to jump to the 'SwissTargetPrediction' webserver. Select the species of 'Homo sapiens', and then paste the SMILES of Sorafenib in the SMILES input box.
Tips: Click on the link to jump to the 'CB-Dock' webserver. Upload the structure file of target predicted by 'SwissTargetPrediction' and the 2D/3D structure file of Sorafenib to perform blind docking.